Couldn’t attend the 2024 ThinkEquity LLC Conference? Watch the full recording of Adial Pharmaceuticals (NASDAQ: ADIL) CEO Cary Claiborne’s presentation, where he discusses our pioneering work in addiction treatment through precision medicine. ?? Watch now: https://lnkd.in/gN92j42m #InvestorConference #AddictionTreatment #PrecisionMedicine
Adial Pharmaceuticals (NASDAQ: ADIL)
制药业
Charlottesville，Virginia 2,189 位关注者
Medicines for Addiction
关于我们
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD? Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
- 网站
-
https://www.adial.com/
Adial Pharmaceuticals (NASDAQ: ADIL)的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Charlottesville，Virginia
- 类型
- 上市公司
- 创立
- 2010
- 领域
- drug abuse、drug addiction、alcohol abuse和alcohol addiction
地点
-
主要
获取路线
1108 Seminole Trail
US，Virginia，Charlottesville
Adial Pharmaceuticals (NASDAQ: ADIL)员工
动态
-
A report by Inside Precision Medicine offers valuable insights into the genetics of Alcohol Use Disorder (AUD). A study at RTI International identified hundreds of genes in key brain regions linked to addiction. At Adial Pharmaceuticals (NASDAQ: ADIL), understanding the genetic underpinnings of AUD supports our commitment to advancing more precise, genetically targeted treatments. Read more here: https://lnkd.in/e-BXZ4Z5 #AUD #GeneticResearch #PrecisionMedicine
-
-
Adial Pharmaceuticals (NASDAQ: ADIL) announces positive topline results from the AD04-103 pharmacokinetics (PK) study for AD04, our investigational treatment for Alcohol Use Disorder (#AUD). The study confirmed the relative bioavailability of AD04 to the reference standard, showed dose-proportional increases in PK exposure, and demonstrated no food effect. The PK study findings also further confirm the safety and tolerability of AD04. This milestone supports our Phase 3 design and upcoming FDA discussions. For more: https://bit.ly/3CvGbN1 #AlcoholUseDisorder #ClinicalTrials
-
-
Adial Pharmaceuticals (NASDAQ: ADIL) reports third quarter 2024 financial results and provides a business update. More here: https://bit.ly/3ADahxA
-
-
Adial Pharmaceuticals (NASDAQ: ADIL) welcomes Vinay Shah as our new Chief Financial Officer. With over 25 years of experience in finance within the pharmaceutical and healthcare sectors, Vinay brings expertise in financial strategy, investor relations, and operational efficiency. For more: https://lnkd.in/e6G96mtv #InvestorRelations #FinanceFunction
-
-
Benzinga reports on Adial Pharmaceuticals (NASDAQ: ADIL) newly applied U.S. patent, expanding intellectual property protection for AD04, our investigational treatment for Alcohol Use Disorder (AUD). This latest patent application broadens AD04’s precision medicine approach by covering additional genotype combinations identified through a genetic diagnostic tool. Read more: https://bit.ly/4f4LQYN #AUD #PrecisionMedicine #GeneticDiagnostics
-
-
In life sciences, a patient-focused mindset is crucial. Watch as Cary Claiborne, CEO of Adial Pharmaceuticals (NASDAQ: ADIL), emphasizes the commitment to advancing patient care and therapeutic innovation. Or watch the full interview with Jeff Harmon on his Conversations Life Science Leaders Aren’t Having series: https://bit.ly/40q5PfU #PatientCare #HealthcareInnovation #ThoughtLeadership
-
Adial Pharmaceuticals (NASDAQ: ADIL) is participating in the 2024 ThinkEquity LLC Conference on October 30th in New York. CEO Cary Claiborne will share insights into our work in developing therapies for addiction treatment and prevention. For more: https://bit.ly/4dYhmWX The presentation will also be live-streamed: https://bit.ly/4hvPE7d. #InvestorConference #AddictionTreatment
-
-
An article in Benzinga features Adial Pharmaceuticals (NASDAQ: ADIL)’ AD04 (low-dose ondansetron), highlighting its clinical results, strong safety profile, and high patient compliance. AD04 is positioned as a promising treatment for Alcohol Use Disorder (AUD), offering a more precision medicine approach. Read more about the findings: https://bit.ly/4begU5r #GeneticDiagnostics #PersonalizedMedicine
-
-
An article from The Pew Charitable Trusts highlights an important issue—medications for alcohol use disorder (AUD) are effective but remain seriously underused. The lack of awareness and stigma surrounding treatment options contribute to this gap. As Adial Pharmaceuticals (NASDAQ: ADIL) continues its work to address unmet needs in AUD treatment, it is crucial to spotlight how better education can improve patient outcomes. https://lnkd.in/ghp8kdG2 #AUD #AlcoholUseDisorder #HealthcareInnovation
-